The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.
Government spokesman Thanakorn Wangboonkongchana said the drug, branded as Evusheld, was developed by AstraZeneca and registered in June last year.
